Pfizer’s Strategic Deal with the Trump Administration: A Masterstroke in Corporate Diplomacy In a move that has sent ripples through the pharmaceutical and political landscapes, Pfizer has announced a landmark agreement with the Trump administration to lower drug prices and invest heavily in domestic manufacturing. This three-year agreement, which runs through the end of the… Continue reading A Masterstroke in Corporate Diplomacy
The Broader Context of Drug Repurposing
Introduction: Shifting the Paradigm in Alzheimer’s Research The landscape of Alzheimer’s disease (AD) research is undergoing a significant transformation. For decades, the focus has been on the amyloid hypothesis, with a multitude of clinical trials targeting amyloid-beta plaques, often with disappointing results. However, recent developments, including the NIA’s strategic funding of novel approaches, signal a… Continue reading The Broader Context of Drug Repurposing
Gait Variability in Parkinson’s Disease: A Researcher White Paper (2022–2025)
Executive Summary Gait variability—particularly stride-time variability (STV) and stride-length variability—has emerged as a promising but context-dependent digital signal for Parkinson’s disease (PD). Across recent studies, STV is repeatedly sensitive to disease state and intervention effects, yet its interpretability hinges on speed control, environment (overground vs treadmill), fatigue, footwear, and surface. Real-world, continuous measurement via wearables… Continue reading Gait Variability in Parkinson’s Disease: A Researcher White Paper (2022–2025)
